secwatch.observer — SEC 8-K summary
======================================

Issuer:     NOVAVAX INC (NVAX)
CIK:        0001000694
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0001104659-24-002100
Event type: earnings
Sentiment:  neutral
Materiality: 0.40
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Novavax reaffirms FY2023 combined R&D and SG&A expense guidance of $1.15-1.25B
------------------------------------------------------------------------------

- Reaffirmed full-year 2023 combined R&D and SG&A expenses anticipated between $1.15B and $1.25B.
- Preliminary data as company finalizes 2023 financial results; Ernst & Young not audited.
- Update provided at 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024.
- Additional material information expected in final financial statements; caution against undue reliance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1000694/000110465924002100/0001104659-24-002100-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1000694/000110465924002100/tm242356d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-002100

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer